Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension

References

• Rubin LJ. Pulmonary arterial hypertension. Proc Am Thorac Soc. 2006;3(1):111–115. PMID: 16493158. doi:10.1513/pats.200510-112JH
   PubMedGoogle Scholar
• Galiè N, McLaughlin VV, Rubin LJ, et al. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019;53(1):1802148. PMID: 30552088. doi:10.1183/13993003.02148-2018
   PubMed Web of Science ®Google Scholar
• Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. PMID: 30545968. doi:10.1183/13993003.01913-2018
   PubMed Web of Science ®Google Scholar
• Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res. 2006;99(7):675–691. PMID: 17008597. doi:10.1161/01.RES.0000243584.45145.3f
   PubMed Web of Science ®Google Scholar
• Stacher E, Graham BB, Hunt JM, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186(3):261–272. PMID: 22679007. doi:10.1164/rccm.201201-0164OC
   PubMed Web of Science ®Google Scholar
• Tuder RM, Archer SL, Dorfmüller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D4–D12. PMID: 24355640. doi:10.1016/j.jacc.2013.10.025
   PubMed Web of Science ®Google Scholar
• Humbert M, Montani D, Perros F, et al. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascul Pharmacol. 2008;49:113–118. PMID: 18606248. doi:10.1016/j.vph.2008.06.003
   PubMed Web of Science ®Google Scholar
• Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Investig. 2012;122:4306–4313. PMID: 23202738. doi:10.1172/JCI60658
   PubMed Web of Science ®Google Scholar
• Cohen-Kaminsky S, Hautefort A, Price L, et al. Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. Drug Discov Today. 2014;19:1251–1256. PMID: 24747559. doi:10.1016/j.drudis.2014.04.007
   PubMed Web of Science ®Google Scholar
• Ryan J, Dasgupta A, Huston J, et al. Mitochondrial dynamics in pulmonary arterial hypertension. J Mol Med. 2015;93:229–242. PMID: 25672499. doi:10.1007/s00109-015-1263-5
   PubMed Web of Science ®Google Scholar
• Potus F, Ruffenach G, Dahou A, et al. Downregulation of MicroRNA-126 contributes to the failing right ventricle in pulmonary arterial hypertension. Circulation. 2015;132:932–943. PMID: 26162916. doi:10.1161/CIRCULATIONAHA.115.016382
   PubMed Web of Science ®Google Scholar
• Potus F, Malenfant S, Graydon C, et al. Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2014;190:318–328. PMID: 2497762. doi:10.1164/rccm.201402-0383OC
   PubMed Web of Science ®Google Scholar
• Ranchoux B, Antigny F, Rucker-Martin C, et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation. 2015;131:1006–1018. PMID: 25593290. doi:10.1161/CIRCULATIONAHA.114.008750
   PubMed Web of Science ®Google Scholar
• Kherbeck N, Tamby MC, Bussone G, et al. The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin Rev Allergy Immunol. 2013;44:31–38. PMID: 21394427. doi:10.1007/s12016-011-8265-z
   PubMed Web of Science ®Google Scholar
• Malenfant S, Neyron AS, Paulin R, et al. Signal transduction in the development of pulmonary arterial hypertension. Pulm Circ. 2013;3:278–293. PMID: 24015329. doi:10.4103/2045-8932.114752
   PubMed Web of Science ®Google Scholar
• Perros F, Humbert M, Cohen-Kaminsky S. Pulmonary arterial hypertension: a flavor of autoimmunity. Méd Sci. 2013;29:607–616. PMID: 23859515. doi:10.1051/medsci/2013296013.12
   Google Scholar
• Montani D, Günther S, Dorfmüller P, et al. Pulmonary arterial hypertension. Orphanet J Rare Dis. 2013;8:97. PMID: 23829793. doi:10.1186/1750-1172-8-97
   PubMed Web of Science ®Google Scholar
• Toshner M, Tajsic T, Morrell NW. Pulmonary hypertension: advances in pathogenesis and treatment. Br Med Bull. 2010;94:21–32. PMID: 20447940. doi:10.1093/bmb/ldq012
   Web of Science ®Google Scholar
• Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1Suppl):S20–31. PMID: 19555855. doi:10.1016/j.jacc.2009.04.018
   Web of Science ®Google Scholar
• Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation. 1970;42:1163–1184. doi:10.1161/01.CIR.42.6.1163
   Web of Science ®Google Scholar
• Caruso P, Dunmore BJ, Schlosser K, et al. Identification of MicroRNA‐124 as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension via PTBP1 (polypyrimidine tract binding protein) and pyruvate kinase M2. Circulation. 2017;136:2451–2467. PMID: 28971999. doi:10.1161/CIRCULATIONAHA.117.028034
   PubMed Web of Science ®Google Scholar
• Lane KB, Machado RD, Pauciulo MW, et al.; Consortium IP. Heterozygous germline mutations in BMPR2, encoding a TGF‐beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26:81–84. PMID: 10973254. doi:10.1038/79226
   PubMed Web of Science ®Google Scholar
• Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation. 2010;121:2045–2066. PMID: 20458021. doi:10.1161/CIRCULATIONAHA.108.847707
   PubMed Web of Science ®Google Scholar
• Landsberg JW, Yuan JX. Calcium and TRP channels in pulmonary vascular smooth muscle cell proliferation. News Physiol Sci. 2004;19:44–50. PMID: 15016901. doi:10.1152/nips.01457.2003
   Google Scholar
• Archer SL. Pyruvate kinase and Warburg metabolism in pulmonary arterial hypertension: uncoupled glycolysis and the cancer‐like phenotype of pulmonary arterial hypertension. Circulation. 2017;136:2486–2490. PMID: 29255124. doi:10.1161/CIRCULATIONAHA.117.031655
   Web of Science ®Google Scholar
• Zhang H, Wang D, Li M, et al. Metabolic and proliferative state of vascular adventitial fibroblasts in pulmonary hypertension is regulated through a MicroRNA‐124/PTBP1 (polypyrimidine tract binding protein 1)/pyruvate kinase muscle axis. Circulation. 2017;136:2468–2485. PMID: 28972001 F. doi:10.1161/CIRCULATIONAHA.117.028069
   PubMed Web of Science ®Google Scholar
• Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 2014;115:165–175. PMID: 24951765. doi:10.1161/CIRCRESAHA.113.301141
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, et al.; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119. PMID: 26320113. doi:10.1093/eurheartj/ehv317
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156–163. PMID: 20585011. doi:10.1161/CIRCULATIONAHA.109.911818
   PubMed Web of Science ®Google Scholar
• Fujii M, Takeda K, Imamura T, et al. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell. 1999;10(11):3801–3813. PMID: 10564272. doi:10.1091/mbc.10.11.3801
   Web of Science ®Google Scholar
• Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 2005;16(3):251–263. PMID: 15871923. doi:10.1016/j.cytogfr.2005.01.009
   PubMed Web of Science ®Google Scholar
• Machado RD, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1Suppl):S32–42. PMID: 19555857. doi:10.1016/j.jacc.2009.04.015
   Web of Science ®Google Scholar
• Valdimarsdottir G, Goumans MJ, Rosendahl A, et al. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation. 2002;106(17):2263–2270. PMID: 12390958. doi:10.1161/01.cir.0000033830.36431.46
   PubMed Web of Science ®Google Scholar
• Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res. 2006;98(2):209–217. PMID: 16357305. doi:10.1161/01.RES.0000200180.01710.e6
   PubMed Web of Science ®Google Scholar
• Soon E, Crosby A, Southwood M, et al. Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192(7):859–872. PMID: 26073741. doi:10.1164/rccm.201408-1509OC18
   Web of Science ®Google Scholar
• de Jesus Perez VA, Alastalo T-P, Wu JC, et al. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol. 2009;184(1):83–99. PMID: 19139264. doi:10.1083/jcb.200806049
   Web of Science ®Google Scholar
• Hansmann G, de Jesus Perez VA, Alastalo TP, et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest. 2008;118:1846–1857. PMID: 18382765. doi:10.1172/jci32503
   PubMed Web of Science ®Google Scholar
• Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev. 1998;9(1):49–61. PMID: 9720756. doi:10.1016/s1359-6101(97)00036-1
   PubMed Web of Science ®Google Scholar
• Massagué J, Chen YG. Controlling TGF-beta signaling. Genes Dev. 2000;14(6):627–644. PMID: 10733523.
   PubMed Web of Science ®Google Scholar
• Attisano L, Wrana J. Signal transduction by the TGF-beta superfamily. Science. 2002;296(5573):1646–1647. PMID: 12040180. doi:10.1126/science.1071809
   PubMed Web of Science ®Google Scholar
• Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000;67(3):737–744. PMID: 10903931. doi:10.1086/303059
   PubMed Web of Science ®Google Scholar
• Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet. 2000;37:741–745. PMID: 11015450. doi:10.1136/jmg.37.10.741
   PubMed Web of Science ®Google Scholar
• Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002;105(14):1672–1678. PMID: 11940546. doi:10.1161/01.CIR.0000012754.72951.3D
   PubMed Web of Science ®Google Scholar
• Austin ED, Hamid R, Hemnes AR, et al. BMPR2 expression is suppressed by signaling through the estrogen receptor. Biol Sex Differ. 2012;3(1):6. PMID: 22348410. doi:10.1186/2042-6410-3-6
   PubMed Web of Science ®Google Scholar
• West J, Fagan K, Steudel W, et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res. 2004;94(8):1109–1114. PMID: 15031260. doi:10.1161/01.RES.0000126047.82846.20
   Web of Science ®Google Scholar
• Hong KH, Lee YJ, Lee E, et al. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation. 2008;118(7):722–730. PMID: 18663089. doi:10.1161/CIRCULATIONAHA.107.736801
   Web of Science ®Google Scholar
• Morrell NW, Yang X, Upton PD, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation. 2001;104:790–795. PMID: 11502704. doi:10.1161/hc3201.094152
   PubMed Web of Science ®Google Scholar
• Fung JJ. Tacrolimus and transplantation: a decade in review. Transplantation. 2004;77(9):S41–S43. PMID: 15201685. doi:10.1097/01.tp.0000126926.61434.a5
   Web of Science ®Google Scholar
• Spiekerkoetter E, Tian X, Cai J, et al. FK506 activates BMPR-II, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest. 2013;123:3600–3613. PMID: 23867624. doi:10.1172/JCI65592
   PubMed Web of Science ®Google Scholar
• Spiekerkoetter E, Sung YK, Sudheendra D, et al. Low-dose FK506 (tacrolimus) in end-stage pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;192(2):254–257. PMID: 26177174. doi:10.1164/rccm.201411-2061LE
   PubMed Web of Science ®Google Scholar
• Spiekerkoetter E, Sung YK, Sudheendra D, et al. Randomised placebo controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension. Eur Respir J. 2017;50:1602449. PMID: 28893866. doi:10.1183/13993003.02449-2016
   Web of Science ®Google Scholar
• Al‐Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70:1608–1621. PMID: 25693996. doi:10.1093/jac/dkv018
   PubMed Web of Science ®Google Scholar
• Long L, Yang X, Southwood M, et al. Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type ii receptor degradation. Circ Res. 2013;112(8):1159–1170. PMID: 23446737. doi:10.1161/CIRCRESAHA.111.300483
   PubMed Web of Science ®Google Scholar
• Humbert M, McLaughlin V, Gibbs JSR, et al.; PULSAR Trial Investigators. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021;384(13):1204–1215. PMID: 33789009. doi:10.1056/NEJMoa2024277
   PubMed Web of Science ®Google Scholar
• Goldenberg NM, Steinberg BE. Inflammation drives pulmonary arterial hypertension. Anesthesiology. 2019;130(5):820–821. PMID: 30994559. doi:10.1097/ALN.0000000000002561
   Web of Science ®Google Scholar
• Mouthon L, Guillevin L, Humbert M. Pulmonary arterial hypertension: an autoimmune disease? Eur Respir J. 2005;26:986–988. PMID: 16319325. doi:10.1183/09031936.05.00112105
   Web of Science ®Google Scholar
• Nicolls MR, Taraseviciene-Stewart L, Rai PR, et al. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J. 2005;26:1110–1118. PMID: 16319344. doi:10.1183/09031936.05.00045705
   PubMed Web of Science ®Google Scholar
• Rabinovitch M. Autoimmune disease and unexplained pulmonary hypertension. Circulation. 1992;85:380–381. PMID: 1728476. doi:10.1161/01.cir.85.1.380
   Web of Science ®Google Scholar
• Perros F, Dorfmuller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;185:311–321. PMID: 22108206. doi:10.1164/rccm.201105-0927OC
   PubMed Web of Science ®Google Scholar
• Dorfmuller P, Perros F, Balabanian K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22:358–363. PMID: 12952274. doi:10.1183/09031936.03.00038903
   PubMed Web of Science ®Google Scholar
• Blum LK, Cao RRL, Sweatt AJ, et al. Circulating plasmablasts are elevated and produce pathogenic anti-endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension. Eur J Immunol. 2018;48:874–884. PMID: 29369345. doi:10.1002/eji.201747460
   Web of Science ®Google Scholar
• de Bourcy CFA, Dekker CL, Davis MM, et al. Dynamics of the human antibody repertoire after B cell depletion in systemic sclerosis. Sci Immunol. 2017;2(15):eaan8289. PMID: 28963118. doi:10.1126/sciimmunol.aan8289
   Web of Science ®Google Scholar
• Huertas A, Phan C, Bordenave J, et al. Regulatory T cell dysfunction in idiopathic, heritable and connective tissue-associated pulmonary arterial hypertension. Chest. 2016;149:1482–1493. PMID: 26836928. doi:10.1016/j.chest.2016.01.004
   Web of Science ®Google Scholar
• Hautefort A, Girerd B, Montani D, et al. T-helper 17 cell polarization in pulmonary arterial hypertension. Chest. 2015;147:1610–1620. PMID: 25429518. doi:10.1378/chest.14-1678
   Web of Science ®Google Scholar
• Savai R, Pullamsetti SS, Kolbe J, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186:897–908. PMID: 22955318. doi:10.1164/rccm.201202-0335OC
   PubMed Web of Science ®Google Scholar
• Klinke A, Berghausen E, Friedrichs K, et al. Myeloperoxidase aggravates pulmonary arterial hypertension by activation of vascular Rho-kinase. JCI Insight. 2018;3(11):e97530. PMID: 29875311. doi:10.1172/jci.insight.97530
   Web of Science ®Google Scholar
• Harbaum L, Baaske KM, Simon M, et al. Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension. BMC Pulm Med. 2017;17(1):72. PMID: 28446163. doi:10.1186/s12890-017-0407-5
   Web of Science ®Google Scholar
• Taylor S, Dirir O, Zamanian RT, et al. The role of neutrophils and neutrophil elastase in pulmonary arterial hypertension. Front Med (Lausanne). 2018;5:217. PMID: 30131961. doi:10.3389/fmed.2018.00217
   Web of Science ®Google Scholar
• Marsh LM, Jandl K, Grünig G, et al. The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2018;51(1):1701214. PMID: 29371380. doi:10.1183/13993003.01214-2017
   PubMed Web of Science ®Google Scholar
• Cracowski JL, Chabot F, Labarere J, et al. Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. Eur Respir J. 2014;43:915–917. PMID: 24232704. doi:10.1183/16000617.0084-2016387
   PubMed Web of Science ®Google Scholar
• Molossi S, Clausell N, Rabinovitch M. Reciprocal induction of tumor necrosis factor-alpha and interleukin-1 beta activity mediates fibronectin synthesis in coronary artery smooth muscle cells. J Cell Physiol. 1995;163:19–29. PMID: 7896895. doi:10.1002/jcp.1041630104
   PubMed Web of Science ®Google Scholar
• Jones PL, Cowan KN, Rabinovitch M. Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol. 1997;150:1349–1360. PMID: 9094991.
   PubMed Web of Science ®Google Scholar
• Courboulin A, Tremblay VL, Barrier M, et al. Krüppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res. 2011;12:128. PMID: 21951574F. doi:10.1186/1465-9921-12-128
   PubMedGoogle Scholar
• Frid MG, Brunetti JA, Burke DL, et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol. 2006;168:659–669. PMID: 16436679. doi:10.2353/ajpath.2006.050599
   PubMed Web of Science ®Google Scholar
• Ito T, Okada T, Miyashita H, et al. Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ Res. 2007;101:734–741. PMID: 17673672. doi:10.1161/CIRCRESAHA.107.153023
   PubMed Web of Science ®Google Scholar
• Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J. 2011;75:2668–2674. PMID: 21873802. doi:10.1253/circj.cj-11-0473
   PubMed Web of Science ®Google Scholar
• Kommireddy S, Bhyravavajhala S, Kurimeti K, et al. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study. Rheumatology (Oxford). 2015;54:1673–1679. PMID: 25929760. doi:10.1093/rheumatology/kev097
   Web of Science ®Google Scholar
• Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, et al. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med. 2007;175:1280–1289. PMID: 17413127. doi:10.1164/rccm.200608-1189OC
   PubMed Web of Science ®Google Scholar
• Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009;104:236–244. PMID: 19074475. doi:10.1161/CIRCRESAHA.108.182014
   PubMed Web of Science ®Google Scholar
• Savale L, Tu L, Rideau D, et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009;10(1):6. PMID: 19173740. doi:10.1186/1465-9921-10-6
   PubMed Web of Science ®Google Scholar
• Tamura Y, Phan C, Tu L, et al. Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. J Clin Investig. 2018;128:1956–1970. PMID: 29629897. doi:10.1172/JCI96462
   PubMed Web of Science ®Google Scholar
• Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;151:1628–1631. PMID: 7735624. doi:10.1164/ajrccm.151.5.7735624
   PubMed Web of Science ®Google Scholar
• Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122:920–927. PMID: 20713898. doi:10.1161/CIRCULATIONAHA.109.933762
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Shimazaki C, Fujimoto Y, et al. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman’s disease. Int J Hematol. 2009;90(1):99–102. PMID: 19554396. doi:10.1007/s12185-009-0346-x
   PubMed Web of Science ®Google Scholar
• Arita Y, Sakata Y, Sudo T, et al. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman’s disease. Heart Vessels. 2010;25(5):444–447. PMID: 20676969. doi:10.1007/s00380-009-1215-5
   PubMed Web of Science ®Google Scholar
• Kadavath S, Zapantis E, Zolty R, et al. A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still’s disease: targeting IL-6. Int J Rheum Dis. 2014;17(3):336–340. PMID: 24581387. doi:10.1111/1756-185X.12324
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Tuder RM, Bridges J, Arend WP. Interleukin‐1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol. 1994;11:664–675. PMID: 7946395. doi:10.1165/ajrcmb.11.6.7946395
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Tuder R. Interleukin-1 receptor antagonist inhibits pulmonary hypertension induced by inflammation. Ann N Y Acad Sci. 1994;725:104–109. PMID: 8030981. doi:10.1111/j.1749-6632.1994.tb39794.x
   Web of Science ®Google Scholar
• Pickworth J, Rothman A, Iremonger J, et al. Differential IL‐1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodeling. Pulm Circ. 2017;7:768–776. PMID: 28828907. doi:10.1177/2045893217729096
   Web of Science ®Google Scholar
• Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36:1118–1125. PMID: 19447938. doi:10.3899/jrheum.090074
   PubMed Web of Science ®Google Scholar
• Trankle CR, Canada JM, Kadariya D, et al. Interleukin‐1 (IL‐1) blockade reduces inflammation in pulmonary arterial hypertension and right ventricular failure: a single‐arm, open‐label, phase IB/II pilot study. Am J Respir Crit Care Med. 2019;199(3):381–384. PMID: 30418047. doi:10.1164/rccm.201809-1631LE
   Web of Science ®Google Scholar
• Zhang LL, Lu J, Li MT, et al. Preventive and remedial application of etanercept attenuate monocrotaline‐induced pulmonary arterial hypertension. Int J Rheum Dis. 2016;19:192–198. PMID: 24612527. doi:10.1111/1756-185X.12304
   Web of Science ®Google Scholar
• Fujita M, Shannon JM, Irvin CG, et al. Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2001;280(1):L39–49. PMID: 11133493. doi:10.1152/ajplung.2001.280.1.L39
   PubMed Web of Science ®Google Scholar
• Li XQ, Wang HM, Yang CG, et al. Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats. Acta Pharmacol Sin. 2011;32(2):217–222. PMID: 21217769. doi:10.1038/aps.2010.187
   Web of Science ®Google Scholar
• Chen D, Zhou D, Qian J, et al. Atorvastatin prevents dehydromonocrotaline-induced pulmonary hypertension in beagles. Exp Lung Res. 2012;38(7):333–343. PMID: 22888849. doi:10.3109/01902148.2012.702852
   PubMed Web of Science ®Google Scholar
• Hurst LA, Dunmore BJ, Long L, et al. TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling. Nat Commun. 2017;8:14079. PMID: 28084316. doi:10.1038/ncomms14079
   Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: FC fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253–259. PMID: 9920948. doi:10.1056/NEJM199901283400401
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130:478–486. PMID: 10075615. doi:10.7326/0003-4819-130-6-199903160-00004
   PubMed Web of Science ®Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta‐analysis. Am J Gastroenterol. 2011;106:644–659. PMID: 21407183. doi:10.1038/ajg.2011.73
   PubMed Web of Science ®Google Scholar
• Mease PJ. Tumor necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis. 2002;61:298–304. PMID: 11874829. doi:10.1136/ard.61.4.298
   PubMed Web of Science ®Google Scholar
• Mutschler D, Wikström G, Lind L, et al. Etanercept reduces late endotoxin-induced pulmonary hypertension in the pig. J Interferon Cytokine Res. 2006;26(9):661–667. PMID: 16978070. doi:10.1089/jir.2006.26.661
   PubMed Web of Science ®Google Scholar
• Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-κB: a blossoming of relevance to human pathobiology. Cell. 2017;168:37–57. PMID: 28086098. doi:10.1016/j.cell.2016.12.012
   PubMed Web of Science ®Google Scholar
• Sawada H, Mitani Y, Maruyama J, et al. A nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest. 2007;132:1265–1274. PMID: 17934115. doi:10.1378/chest.06-2243
   Web of Science ®Google Scholar
• Price LC, Caramori G, Perros F, et al. Nuclear factor κ-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension. PLoS One. 2013;8(10):e75415. PMID: 24124488. doi:10.1371/journal.pone.0075415
   Web of Science ®Google Scholar
• Chin MP, Bakris GL, Block GA, et al. Bardoxolone methyl improves kidney function in patients with chronic kidney disease stage 4 and type 2 diabetes: post-hoc analyses from bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes study. Am J Nephrol. 2018;47:40–47. PMID: 29402767. doi:10.1159/000486398
   PubMed Web of Science ®Google Scholar
• Oudiz R, Meyer C, Chin M, et al. Initial data report from “LARIAT”: a phase 2 study of bardoxolone methyl in PAH patients on stable background therapy. Chest. 2015;148:639 A. doi:10.1378/chest.2345856
   Web of Science ®Google Scholar
• Grzegorzewska AP, Seta F, Han R, et al. Dimethyl fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways. Sci Rep. 2017;7:41605. PMID: 28150703. doi:10.1038/srep41605
   Web of Science ®Google Scholar
• Zhao G, Liu Y, Fang J, et al. Dimethyl fumarate inhibits the expression and function of hypoxia-inducible factor-1α (HIF-1α). Biochem Biophys Res Commun. 2014;448:303–307. PMID: 24569076. doi:10.1016/j.bbrc.2014.02.062
   PubMed Web of Science ®Google Scholar
• Bosch X, Ramos-Casals M, Khamashta MA. Drugs Targeting B-Cells in Autoimmune Diseases. Springer Science & Business Media; 2013:1–4.
   Google Scholar
• Nicolls M, Badesch D, Chung L, et al.; ASC01 Investigators. Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension in a multi-center NIH Clinical Trial. Arthritis Rheumatol. 2019;71(S10):Abstract 0867.
   Google Scholar
• Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009;54:S10–19. PMID: 19555853. doi:10.1016/j.jacc.2009.04.006
   PubMed Web of Science ®Google Scholar
• Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178:81–88. PMID: 18420966. doi:10.1164/rccm.200707-1037OC
   PubMed Web of Science ®Google Scholar
• Medarametla V, Festin S, Sugarragchaa C, et al. PK10453, a nonselective platelet-derived growth factor receptor inhibitor, prevents the progression of pulmonary arterial hypertension. Pulm Circ. 2014;4(1):82–102. PMID: 25006424. doi:10.1086/674881
   PubMed Web of Science ®Google Scholar
• Klein M, Schermuly RT, Ellinghaus P, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation. 2008;118(20):2081–2090. PMID: 18955668. doi:10.1161/CIRCULATIONAHA.108.779751
   PubMed Web of Science ®Google Scholar
• Redner RL. Why doesn’t imatinib cure chronic myeloid leukemia? Oncologist. 2010;15(2):182–186. PMID: 20124443. doi:10.1634/theoncologist.2009-0297
   Web of Science ®Google Scholar
• Dagher R, Cohen M, Williams G. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8:3034–3038. PMID: 12374669.
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115(10):2811–2821. PMID: 16200212. doi:10.1172/JCI24838
   PubMed Web of Science ®Google Scholar
• Patterson KC, Weissmann A, Ahmadi T, et al. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med. 2006;145(2):152–153. PMID: 16847299. doi:10.7326/0003-4819-145-2-200607180-00020
   PubMed Web of Science ®Google Scholar
• ten Freyhaus H, Dumitrescu D, Berghausen E, et al. Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs. 2012;21(1):119–134. PMID: 22074410. doi:10.1517/13543784.2012.632408
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182(9):1171–1177. PMID: 20581169. doi:10.1164/rccm.201001-0123OC
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127(10):1128–1138. PMID: 23403476. doi:10.1161/CIRCULATIONAHA.112.000765
   PubMed Web of Science ®Google Scholar
• Shah AM, Campbell P, Rocha GQ, et al. Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension. Eur Heart J. 2015;36(10):623–632. PMID: 24566799. doi:10.1093/eurheartj/ehu035
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–134. PMID: 17215530. doi:10.1056/NEJMoa060655
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. PMID: 18650514. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Man CH, Fung TK, Ho C, et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood. 2012;119(22):5133–5143. PMID: 22368270. doi:10.1182/blood-2011-06-363960
   PubMed Web of Science ®Google Scholar
• Worden F. Treatment strategies for radioactive iodine refractory differentiated thyroid cancer. Ther Adv Med Oncol. 2014;6(6):267–279. PMID: 25364392. doi:10.1177/1758834014548188
   Web of Science ®Google Scholar
• Ranieri G, Gadaleta-Caldarola G, Goffredo V, et al. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr Med Chem. 2012;19(7):938–944. PMID: 22214462. doi:10.2174/092986712799320736
   PubMed Web of Science ®Google Scholar
• Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics. 2008;33(2):278–291. PMID: 18303084. doi:10.1152/physiolgenomics.00169.2007
   Web of Science ®Google Scholar
• Kimura G, Kataoka M, Inami T, et al. Sorafenib as a potential strategy for refractory pulmonary arterial hypertension. Pulm Pharmacol Ther. 2017;44:46–49. PMID: 28315488. doi:10.1016/j.pupt.2017.03.009
   Web of Science ®Google Scholar
• Gomberg-Maitland M, Maitland ML, Barst RJ, et al. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2010;87(3):303–310. PMID: 20010555. doi:10.1038/clpt.2009.217
   PubMed Web of Science ®Google Scholar
• Manley P, Cowan-Jacob S, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta. 2005;1754(1–2):3–13. PMID: 16172030. doi:10.1016/j.bbapap.2005.07.040
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: an evidence-based review. Core Evid. 2010;4:207–213. PMID: 20694077. doi:10.2147/ce.s6003
   PubMedGoogle Scholar
• Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol. 2007;18(Suppl 6):vi42–6. PMID: 17591830. doi:10.1093/annonc/mdm223
   Web of Science ®Google Scholar
• Breccia M, Alimena G. Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia. Leuk Res. 2010;34(2):129–134. PMID: 19783301. doi:10.1016/j.leukres.2009.08.031
   Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542–2551. PMID: 16775235. doi:10.1056/NEJMoa055104
   PubMed Web of Science ®Google Scholar
• Keating GM. Dasatinib: a review in chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia. Drugs. 2017;77(1):85–96. PMID: 28032244. doi:10.1007/s40265-016-0677-x
   Web of Science ®Google Scholar
• Dumitrescu D, Seck C, ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2011;38(1):218–220. PMID: 21719499. doi:10.1183/09031936.00154210
   Web of Science ®Google Scholar
• Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–2137. PMID: 22451584. doi:10.1161/CIRCULATIONAHA.111.079921
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng XR, Riddick N, et al. ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. Circ Res. 2009;104(4):531–540. PMID: 19131646. doi:10.1161/CIRCRESAHA.108.188524
   PubMed Web of Science ®Google Scholar
• Fagan KA, Oka M, Bauer NR, et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol. 2004;287:L656–L664. PMID: 14977625. doi:10.1152/ajplung.00090.2003
   PubMed Web of Science ®Google Scholar
• Loirand G, Guérin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98(3):322–334. PMID: 16484628. doi:10.1161/01.RES.0000201960.04223.3c
   PubMed Web of Science ®Google Scholar
• Nagaoka T, Morio Y, Casanova N, et al. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol. 2004;287(4):L665–72. PMID: 12959926. doi:10.1152/ajplung.00050.2003
   Web of Science ®Google Scholar
• Walker J, Undem C, Yun X, Lade J, Jiang H, Shimoda LA. Role of Rho kinase and Na+/H+ exchange in hypoxia-induced pulmonary arterial smooth muscle cell proliferation and migration. Physiol Rep. 2016;4(6):e12702. PMID: 27009277. doi:10.14814/phy2.12702
   Google Scholar
• Madden JA, Ray DE, Keller PA, Kleinman JG. Ion exchange activity in pulmonary artery smooth muscle cells: the response to hypoxia. Am J Physiol Lung Cell Mol Physiol. 2001;280(2):L264–71. PMID: 11159005. doi:10.1152/ajplung.2001.280.2.L264
   Web of Science ®Google Scholar
• McMurtry IF, Bauer NR, Fagan KA, Nagaoka T, Gebb SA, Oka M. Hypoxia and Rho/Rho-kinase signaling. Lung development versus hypoxic pulmonary hypertension. Adv Exp Med Biol. 2003;543:127–137. PMID: 14713118.
   PubMed Web of Science ®Google Scholar
• Wojciak-Stothard B, Tsang LY, Haworth SG. Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2005;288:L749–L760. PMID: 15591411. doi:10.1152/ajplung.00361.2004
   PubMed Web of Science ®Google Scholar
• Guilluy C, Eddahibi S, Agard C, et al. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med. 2009;179(12):1151–1158. PMID: 19299501. doi:10.1164/rccm.200805-691OC
   PubMed Web of Science ®Google Scholar
• Shimokawa H, Hiramori K, Iinuma H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol. 2002;40(5):751–761. PMID: 12409984. doi:10.1097/00005344-200211000-00013
   Web of Science ®Google Scholar
• Tachibana E, Harada T, Shibuya M, et al. Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien). 1999;141(1):13–19. PMID: 10071681. doi:10.1007/s007010050260
   Web of Science ®Google Scholar
• Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol. 2000;522(Pt 2):177–185. PMID: 10639096. doi:10.1111/j.1469-7793.2000.t01-2-00177.x
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005;91(3):391–392. PMID: 15710736. doi:10.1136/hrt.2003.029470
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Yamada N, Matsubara H, et al. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J. 2013;77(10):2619–2625. PMID: 23912836. doi:10.1253/circj.cj-13-0443
   PubMed Web of Science ®Google Scholar
• Liu AJ, Ling F, Wang D, et al. Fasudil inhibits platelet-derived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27kip1 via the ERK signal pathway. Chin Med J (Engl). 2011;124(19):3098–3104. PMID: 22040563.
   PubMed Web of Science ®Google Scholar
• Fujita H, Fukumoto Y, Saji K, et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels. 2010;25(2):144–149. PMID: 20339976. doi:10.1007/s00380-009-1176-8
   PubMed Web of Science ®Google Scholar
• Archer SL, Fang YH, Ryan JJ, Piao L. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm Circ. 2013;3(1):144–152. PMID: 23662191. doi:10.4103/2045-8932.109960
   PubMed Web of Science ®Google Scholar
• Archer SL, Marsboom G, Kim GH, et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation. 2010;121(24):2661–2671. PMID: 20529999F. doi:10.1161/CIRCULATIONAHA.109.916098
   PubMed Web of Science ®Google Scholar
• Sutendra G, Michelakis ED. The metabolic basis of pulmonary arterial hypertension. Cell Metab. 2014;19:558‐ 573. PMID: 24508506. doi:10.1016/j.cmet.2014.01.004
   Web of Science ®Google Scholar
• Ryan JJ, Archer SL. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part I: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension. Circulation. 2015;131:1691‐ 1702. PMID: 25964279. doi:10.1161/CIRCULATIONAHA.114.006979
   Web of Science ®Google Scholar
• Wilkins MR. Pulmonary hypertension: the science behind the disease spectrum. Eur Respir Rev. 2012;21:19–26. PMID: 22379170. doi:10.1183/09059180.00008411
   PubMedGoogle Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123:309‐ 314. PMID: 13298683. doi:10.1126/science.123.3191.309
   Web of Science ®Google Scholar
• Paulin R, Michelakis ED. The metabolic theory of pulmonary arterial hypertension. Circ Res. 2014;115:148–164. PMID: 24951764. doi:10.1161/CIRCRESAHA.115.301130.
   PubMed Web of Science ®Google Scholar
• Michelakis ED, McMurtry MS, Wu XC, et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation. 2002;105:244–250. PMID: 11790708. doi:10.1161/hc0202.101974
   PubMed Web of Science ®Google Scholar
• McMurtry MS, Bonnet S, Wu X, et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004;95:830–840. PMID: 15375007. doi:10.1161/01.RES.0000145360.16770.9f
   PubMed Web of Science ®Google Scholar
• Piao L, Sidhu VK, Fang YH, et al. FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med (Berl). 2013;91:333–346. PMID: 23247844. doi:10.1007/s00109-012-0982-0
   PubMed Web of Science ®Google Scholar
• Michelakis ED, Gurtu V, Webster L, et al. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Sci Transl Med. 2017;9(413):pii: eaao4583. PMID: 29070699. doi:10.1126/scitranslmed.aao4583
   Web of Science ®Google Scholar
• Nelson CH, Etchevers K, Yi S, et al. Pharmacokinetics, safety, and tolerability of selonsertib, an apoptosis signal-regulating kinase 1 (ASK1) inhibitor, following first-in-human single and multiple ascending doses in healthy subjects. Clin Pharmacokinet. 2020;59(9):1109–1117. PMID: 32333325. doi:10.1007/s40262-020-00878-y
   Web of Science ®Google Scholar
• Hawwa N, Menon V. Ranolazine: clinical applications and therapeutic basis. Am J Cardiovasc Drugs. 2013;13(1):5–16. PMID: 23335347. doi:10.1007/s40256-012-0003-2
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–1382. PMID: 15093870. doi:10.1016/j.jacc.2003.11.045
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309–316. PMID: 14734593. doi:10.1001/jama.291.3.309
   PubMed Web of Science ®Google Scholar
• Hasenfuss G, Maier LS. Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol. 2008;97:222–226. PMID: 18046526. doi:10.1007/s00392-007-0612-y
   PubMed Web of Science ®Google Scholar
• Fang YH, Piao L, Hong Z, et al. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle’s cycle. J Mol Med. 2012;90:31–43. PMID: 21874543. doi:10.1007/s00109-011-0804-9
   Web of Science ®Google Scholar
• Gomberg-Maitland M, Schilz R, Mediratta A, et al. Phase I safety study of ranolazine in pulmonary arterial hypertension. Pulm Circ. 2015;5:691–700. PMID: 26697176. doi:10.1086/683813
   Web of Science ®Google Scholar
• Khan SS, Cuttica MJ, Beussink-Nelson L, et al. Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. Pulm Circ. 2015;5(3):547–556. PMID: 26401256. doi:10.1086/682427
   PubMed Web of Science ®Google Scholar
• Han Y, Forfia PR, Vaidya A, et al. Rationale and design of the ranolazine PH-RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension. Open Heart. 2018;5(1):e000736. PMID: 29531764. doi:10.1136/openhrt-2017-000736
   Web of Science ®Google Scholar
• Sutendra G, Bonnet S, Rochefort G, et al. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med. 2010;2(44):44–58. PMID: 20702857. doi:10.1126/scitranslmed.3001327
   Web of Science ®Google Scholar
• Aggarwal S, Gross CM, Sharma S, et al. Reactive oxygen species in pulmonary vascular remodeling. Compr Physiol. 2013;3:1011–1034. PMID: 23897679. doi:10.1002/cphy.c120024
   Web of Science ®Google Scholar
• Fulton D, Li X, Bordan Z, et al. Reactive oxygen and nitrogen species in the development of pulmonary hypertension. Antioxidants (Basel). 2017;6(3):54. PMID: 28684719. doi:10.3390/antiox6030054
   Google Scholar
• Jernigan NL, Naik JS, Weise-Cross L, et al. Contribution of reactive oxygen species to the pathogenesis of pulmonary arterial hypertension. PLoS One. 2017;12(6):e0180455. PMID: 28666030. doi:10.1371/journal.pone.0180455
   Web of Science ®Google Scholar
• Zuo L, Rose BA, Roberts WJ, et al. Molecular characterization of reactive oxygen species in systemic and pulmonary hypertension. Am J Hypertens. 2014;27(5):643–650. PMID: 24552887. doi:10.1093/ajh/hpt292
   Web of Science ®Google Scholar
• Anwar A, Ruffenach G, Mahajan A, et al. Novel biomarkers for pulmonary arterial hypertension. Respir Res. 2016;17(1):88. PMID: 27439993. doi:10.1186/s12931-016-0396-6
   Web of Science ®Google Scholar
• Reis GS, Augusto VS, Silveira APC, et al. Oxidative-stress biomarkers in patients with pulmonary hypertension. Pulm Circ. 2013;3(4):856–861. PMID: 25006401. doi:10.1086/674764
   Web of Science ®Google Scholar
• Zhang S, Yang T, Xu X, et al. Oxidative stress and nitric oxide signaling related biomarkers in patients with pulmonary hypertension: a case control study. BMC Pulm Med. 2015;15:50. PMID: 25934483. doi:10.1186/s12890-015-0045-8
   Web of Science ®Google Scholar
• Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990;87(4):1620–1624. PMID: 2154753. doi:10.1073/pnas.87.4.1620
   PubMed Web of Science ®Google Scholar
• Chen CA, Wang TY, Varadharaj S, et al. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature. 2010;468(7327):1115–1118. PMID: 21179168. doi:10.1038/nature09599
   PubMed Web of Science ®Google Scholar
• Elahi MM, Kong YX, Matata BM. Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev. 2009;2(5):259–269. PMID: 20716913. doi:10.4161/oxim.2.5.9441
   PubMed Web of Science ®Google Scholar
• Bowers R, Cool C, Murphy RC, et al. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med. 2004;169:764–769. PMID: 14701708. doi:10.1164/rccm.200301-147OC
   PubMed Web of Science ®Google Scholar
• Demarco VG, Whaley-Connell AT, Sowers JR, et al. Contribution of oxidative stress to pulmonary arterial hypertension. World J Cardiol. 2010;2:316–324. PMID: 21160609. doi:10.4330/wjc.v2.i10.316
   PubMedGoogle Scholar
• Dorfmüller P, Chaumais M-C, Giannakouli M, et al. Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respir Res. 2011;12:119. PMID: 21906276. doi:10.1186/1465-9921-12-119
   PubMed Web of Science ®Google Scholar
• Black SM, DeVol JM, Wedgwood S. Regulation of fibroblast growth factor-2 expression in pulmonary arterial smooth muscle cells involves increased reactive oxygen species generation. Am J Physiol Cell Physiol. 2008;294:C345–C354. PMID: 17942638. doi:10.1152/ajpcell.00216.2007
   PubMed Web of Science ®Google Scholar
• Montisano DF, Mann T, Spragg RG. H2O2 increases expression of pulmonary artery endothelial cell platelet-derived growth factor mRNA. J Appl Physiol. 1992;73:2255–2262. PMID: 1490932. doi:10.1152/jappl.1992.73.6.2255
   PubMed Web of Science ®Google Scholar
• Wedgwood S, Dettman RW, Black SM. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1058–1067. PMID: 11597896. doi:10.1152/ajplung.2001.281.5.L1058
   PubMed Web of Science ®Google Scholar
• Cheng TH, Shih NL, Chen SY, et al. Reactive oxygen species mediate cyclic strain-induced endothelin-1 gene expression via Ras/Raf/extracellular signal-regulated kinase pathway in endothelial cells. J Mol Cell Cardiol. 2001;33:1805–1814. PMID: 11603923. doi:10.1006/jmcc.2001.1444
   PubMed Web of Science ®Google Scholar
• Tate RM, Morris HG, Schroeder WR, Repine JE. Oxygen metabolites stimulate thromboxane production and vasoconstriction in isolated saline-perfused rabbit lungs. J Clin Investig. 1984;74:608–613. PMID: 6547730. doi:10.1172/JCI111458
   PubMed Web of Science ®Google Scholar
• Lee DS, McCallum EA, Olson DM. Effects of reactive oxygen species on prostacyclin production in perinatal rat lung cells. J Appl Physiol. 1989;66:1321–1327. PMID: 2651389. doi:10.1152/jappl.1989.66.3.1321
   PubMed Web of Science ®Google Scholar
• Brito R, Castillo G, González J, et al. Oxidative stress in hypertension: mechanisms and therapeutic opportunities. Exp Clin Endocrinol Diabetes. 2015;123:325–335. PMID: 25918881. doi:10.1055/s-0035-1548765
   PubMed Web of Science ®Google Scholar
• Block K, Gorin Y, Hoover P, et al. NAD(P)H oxidases regulate HIF-2alpha protein expression. J Biol Chem. 2007;282:8019–8026. PMID: 17200123. doi:10.1074/jbc.M611569200
   PubMed Web of Science ®Google Scholar
• Chandel NS, McClintock DS, Feliciano CE, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia A mechanism of O2 sensing. J Biol Chem. 2000;275:25130–25138. PMID: 10833514. doi:10.1074/jbc.M001914200
   PubMed Web of Science ®Google Scholar
• Gale DP, Harten SK, Reid CDL, et al. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2α mutation. Blood. 2008;112:919–921. PMID: 18650473. doi:10.1182/blood-2008-04-153718
   PubMed Web of Science ®Google Scholar
• Brusselmans K, Compernolle V, Tjwa M, et al. Heterozygous deficiency of hypoxia-inducible factor–2α protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Investig. 2003;111:1519–1527. PMID: 12750401. doi:10.1172/JCI15496
   PubMed Web of Science ®Google Scholar
• Cracowski JL, Cracowski C, Bessard G, et al. Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med. 2001;164:1038–1042. PMID: 11587993. doi:10.1164/ajrccm.164.6.2104033
   PubMed Web of Science ®Google Scholar
• Wong C-M, Bansal G, Pavlickova L, et al. Reactive oxygen species and antioxidants in pulmonary hypertension. Antioxid Redox Signal. 2013;18:1789–1796. PMID: 22657091. doi:10.1089/ars.2012.4568
   Web of Science ®Google Scholar
• Tabima DM, Frizzell S, Gladwin MT. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic Biol Med. 2012;52:1970–1986. PMID: 22401856. doi:10.1016/j.freeradbiomed.2012.02.041
   PubMed Web of Science ®Google Scholar
• Crosswhite P, Sun Z. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens. 2010;28:201–212. PMID: 20051913. doi:10.1097/HJH.0b013e328332bcdb
   PubMed Web of Science ®Google Scholar
• Xu D, Guo H, Xu X, et al. Exacerbated pulmonary arterial hypertension and right ventricular hypertrophy in animals with loss of function of extracellular superoxide dismutase. Hypertens. 2011;58:303–309. PMID: 21730301. doi:10.1161/HYPERTENSIONAHA.110.166819
   PubMed Web of Science ®Google Scholar
• Yu H, Liu J, Dong Y, et al. Anti-hypoxic effect of dihydroartemisinin on pulmonary artery endothelial cells. Biochem Biophys Res Commun. 2018;506:840–846. PMID: 30391003. doi:10.1016/j.bbrc.2018.10.176
   Web of Science ®Google Scholar
• Galhotra P, Prabhakar P, Meghwani H, et al. Beneficial effects of fenofibrate in pulmonary hypertension in rats. Mol Cell Biochem. 2018;449:185–194. PMID: 29761247. doi:10.1007/s11010-018-3355-3
   Web of Science ®Google Scholar
• Türck P, Lacerda DS, Carraro CC, et al. Trapidil improves hemodynamic, echocardiographic and redox state parameters of right ventricle in monocrotaline-induced pulmonary arterial hypertension model. Biomed Pharmacother. 2018;103:182–190. PMID: 29653363. doi:10.1016/j.biopha.2018.04.001
   Web of Science ®Google Scholar
• Zuckerbraun BS, Shiva S, Ifedigbo E, et al. Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation. Circulation. 2010;121:98–109. PMID: 20026772. doi:10.1161/CIRCULATIONAHA.109.891077
   PubMed Web of Science ®Google Scholar
• Baliga RS, Milsom AB, Ghosh SM, et al. Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase. Circulation. 2012;125:2922–2932. PMID: 22572914. doi:10.1161/CIRCULATIONAHA.112.100586
   PubMed Web of Science ®Google Scholar
• Sharp J, Farha S, Park MM, et al. Coenzyme Q supplementation in pulmonary arterial hypertension. Redox Biol. 2014;2:884–891. PMID: 25180165. doi:10.1016/j.redox.2014.06.010
   Web of Science ®Google Scholar
• Archer SL, Nelson DP, Weir EK. Detection of activated O2 species in vitro and in rat lungs by chemiluminescence. J Appl Physiol. 1989;67:1912–1921. PMID: 2532194. doi:10.1152/jappl.1989.67.5.1912
   PubMed Web of Science ®Google Scholar
• Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87–114. PMID: 16507884. doi:10.1124/pr.58.1.6
   PubMed Web of Science ®Google Scholar
• Poss WB, Huecksteadt TP, Panus PC, et al. Regulation of xanthine dehydrogenase and xanthine oxidase activity by hypoxia. Am J Physiol Lung Cell Mol Physiol. 1996;270:L941–L946. PMID: 8764218. doi:10.1152/ajplung.1996.270.6.L941
   Web of Science ®Google Scholar
• Engerson TD, McKelvey TG, Rhyne DB, et al. Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissues. J Clin Invest. 1987;79:1564–1570. PMID: 3294898. doi:10.1172/JCI112990
   PubMed Web of Science ®Google Scholar
• Pritsos CA. Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact. 2000;129:195–208. PMID: 11154741. doi:10.1016/s0009-2797(00)00203-9
   PubMed Web of Science ®Google Scholar
• Houston M, Estevez A, Chumley P, et al. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem. 1999;274:4985–4994. PMID: 9988743. doi:10.1074/jbc.274.8.4985
   PubMed Web of Science ®Google Scholar
• Hoshikawa Y, Ono S, Suzuki S, et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol. 2001;90:1299–1306. PMID: 11247927. doi:10.1152/jappl.2001.90.4.1299
   PubMed Web of Science ®Google Scholar
• Jankov RP, Kantores C, Pan J, Belik J. Contribution of xanthine oxidase‐derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. Am J Physiol Lung Cell Mol Physiol. 2008;294:L233–L245. PMID: 18083771. doi:10.1152/ajplung.00166.2007
   Web of Science ®Google Scholar
• Voelkel MA, Wynne KM, Badesch DB, et al. Hyperuricemia in severe pulmonary hypertension. Chest. 2000;117:19–24. PMID: 10631193. doi:10.1378/chest.117.1.19
   PubMed Web of Science ®Google Scholar
• Bendayan D, Shitrit D, Ygla M, et al. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. Respir Med. 2003;97:130–133. PMID: 12587962. doi:10.1053/rmed.2003.1440
   PubMed Web of Science ®Google Scholar
• Spiekermann S, Schenk K, Hoeper MM. Increased xanthine oxidase activity in idiopathic pulmonary arterial hypertension. Eur Respir J. 2009;34(1):276. PMID: 19567609. doi:10.1183/09031936.00013309
   Web of Science ®Google Scholar
• Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn‐SOD (SOD1), Mn‐SOD (SOD2), and EC‐SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med. 2002;33:337–349. PMID: 12126755. doi:10.1016/s0891-5849(02)00905-x
   PubMed Web of Science ®Google Scholar
• Eble JA, Niland S. The extracellular matrix of blood vessels. Curr Pharm Des. 2009;15:1385–1400. PMID: 19355976. doi:10.2174/138161209787846757
   PubMed Web of Science ®Google Scholar
• Lammers SR, Kao PH, Qi HJ, et al. Changes in the structure-function relationship of elastin and its impact on the proximal pulmonary arterial mechanics of hypertensive calves. Am J Physiol Heart Circ Physiol. 2008;295:H1451–9. PMID: 18660454. doi:10.1152/ajpheart.00127.2008
   Web of Science ®Google Scholar
• Frisdal E, Gest V, Vieillard-Baron A, et al. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J. 2001;18:838–845. PMID: 11757635. doi:10.1183/09031936.01.00084601
   PubMed Web of Science ®Google Scholar
• Ambalavanan N, Nicola T, Li P, et al. Role of matrix metalloproteinase-2 in newborn mouse lungs under hypoxic conditions. Pediatr Res. 2008;63:26–32. PMID: 18043506. doi:10.1203/PDR.0b013e31815b690d
   Web of Science ®Google Scholar
• Novotná J, Herget J. Possible role of matrix metalloproteinases in reconstruction of peripheral pulmonary arteries induced by hypoxia. Physiol Res. 2002;51:323–334. PMID: 12449429.
   PubMed Web of Science ®Google Scholar
• Lepetit H, Eddahibi S, Fadel E, et al. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J. 2005;25:834–842. PMID: 15863640. doi:10.1183/09031936.05.00072504
   PubMed Web of Science ®Google Scholar
• Thenappan T, Chan SY, Weir EK. Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2018;315(5):H1322–H1331. PMID: 30141981. doi:10.1152/ajpheart.00136.2018
   PubMed Web of Science ®Google Scholar
• George J, D’Armiento J. Transgenic expression of human matrix metalloproteinase-9 augments monocrotaline-induced pulmonary arterial hypertension in mice. J Hypertens. 2011;29(2):299–308. PMID: 21063214. doi:10.1097/HJH.0b013e328340a0e4
   Web of Science ®Google Scholar
• Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest. 2000;105(1):21–34. PMID: 10619858. doi:10.1172/JCI6539
   Web of Science ®Google Scholar
• Cowan KN, Heilbut A, Humpl T, et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 2000;6(6):698–702. PMID: 10835689. doi:10.1038/76282
   PubMed Web of Science ®Google Scholar
• Vieillard-Baron A, Frisdal E, Raffestin B, et al. Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer limits monocrotaline-induced pulmonary vascular remodeling in rats. Hum Gene Ther. 2003;14(9):861–869. PMID: 12828857. doi:10.1089/104303403765701150
   Web of Science ®Google Scholar
• Pullamsetti S, Krick S, Yilmaz H, et al. Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respir Res. 2005;6(128):1–14. PMID: 16262900. doi:10.1186/1465-9921-6-128
   Web of Science ®Google Scholar
• Martinez MLL, Lopes LF, Coelho EB, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006;47(1):117–122. PMID: 16262900. doi:10.1097/01.fjc.0000196241.96759.71
   Web of Science ®Google Scholar
• Tayebjee MH, Nadar S, Blann AD, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens. 2004;17(9):764–769. PMID: 15363817. doi:10.1016/j.amjhyper.2004.05.019
   PubMed Web of Science ®Google Scholar
• Mawatari E, Hongo M, Sakai A, et al. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering. Clin Exp Pharmacol Physiol. 2007;34(7):594–600. PMID: 17581214. doi:10.1111/j.1440-1681.2007.04618.x.
   Web of Science ®Google Scholar
• Koo HS, Kim KC, Hong YM. Gene expressions of nitric oxide synthase and matrix metalloproteinase-2 in monocrotaline induced pulmonary hypertension in rats after bosentan treatment. Korean Circ J. 2011;41(2):83–90. PMID: 21430993. doi:10.4070/kcj.2011.41.2.83
   Web of Science ®Google Scholar
• Zaidi SHE, You X-M, Ciura S, et al. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation. 2002;105(4):516–521. PMID: 11815437. doi:10.1161/hc0402.102866
   Web of Science ®Google Scholar
• Nickel NP, Spiekerkoetter E, Gu M, et al. Elafin reverses pulmonary hypertension via caveolin-1-dependent bone morphogenetic protein signaling. Am J Respir Crit Care Med. 2015;191:1273–1286. PMID: 25853696. doi:10.1164/rccm.201412-2291OC
   PubMed Web of Science ®Google Scholar
• Sutliff RL, Kang BY, Hart CM. PPARgamma as a potential therapeutic target in pulmonary hypertension. Ther Adv Respir Dis. 2010;4:143–160. PMID: 20530063. doi:10.1177/1753465809369619
   PubMedGoogle Scholar
• Ameshima S, Golpon H, Cool CD, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res. 2003;92:1162–1169. PMID: 12714563. doi:10.1161/01.RES.0000073585.50092.14
   PubMed Web of Science ®Google Scholar
• Hansmann G, Zamanian RT. PPARgamma activation: a potential treatment for pulmonary hypertension. Sci Transl Med. 2009;1:12–14. PMID: 20371457. doi:10.1126/scitranslmed.3000267
   Web of Science ®Google Scholar
• Tian J, Smith A, Nechtman J, et al. Effect of PPARgamma inhibition on pulmonary endothelial cell gene expression: gene profiling in pulmonary hypertension. Physiol Genomics. 2009;40:48–60. PMID: 19825830. doi:10.1152/physiolgenomics.00094.2009
   Web of Science ®Google Scholar
• Lu X, Murphy TC, Nanes MS, Hart CM. PPAR{gamma} regulates hypoxia-induced Nox4 expression in human pulmonary artery smooth muscle cells through NF-{kappa}B. Am J Physiol Lung Cell Mol Physiol. 2010;299:L559–566. PMID: 20622120. doi:10.1152/ajplung.00090.2010
   Web of Science ®Google Scholar
• Calvier L, Chouvarine P, Legchenko E, Hansmann G. Transforming growth factor β1- and bone morphogenetic protein 2/PPARγ-regulated miRNAs in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2017;196:1227–1228. PMID: 28653861. doi:10.1164/rccm.201705-0923LE
   Web of Science ®Google Scholar
• Calvier L, Chouvarine P, Legchenko E, et al. PPARγ links BMP2 and TGFβ1 pathways in vascular smooth muscle cells, regulating cell proliferation and glucose metabolism. Cell Metab. 2017;25:1118–1134.e7. PMID: 28467929. doi:10.1016/j.cmet.2017.03.011
   PubMed Web of Science ®Google Scholar
• Geraci MW, Moore M, Gesell T, et al. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res. 2001;88:555–562. PMID: 11282888. doi:10.1161/01.res.88.6.555
   PubMed Web of Science ®Google Scholar
• Green DE, Murphy TC, Kang BY, et al. PPARgamma ligands attenuate hypoxia-induced proliferation in human pulmonary artery smooth muscle cells through modulation of MicroRNA-21. PLoS One. 2015;10(7):e0133391. PMID: 26208095. doi:10.1371/journal.pone.0133391
   Web of Science ®Google Scholar
• Matsuda Y, Hoshikawa Y, Ameshima S, et al. Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats. Nihon Kokyuki Gakkai Zasshi. 2005;43:283–288. PMID: 15969209.
   PubMedGoogle Scholar
• Nisbet RE, Bland JM, Kleinhenz DJ, et al. Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am J Respir Cell Mol Biol. 2010;42:482–490. PMID: 19520921. doi:10.1165/rcmb.2008-0132OC
   PubMed Web of Science ®Google Scholar
• Hansmann G, Wagner RA, Schellong S, et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator‐activated receptor‐gamma activation. Circulation. 2007;115:1275–1284. PMID: 17339547. doi:10.1161/CIRCULATIONAHA.106.663120
   PubMed Web of Science ®Google Scholar
• Kim EK, Lee JH, Oh YM, et al. Rosiglitazone attenuates hypoxia‐induced pulmonary arterial hypertension in rats. Respirology. 2010;15:659–668. PMID: 20546541. doi:10.1111/j.1440-1843.2010.01756.x.
   PubMed Web of Science ®Google Scholar
• Behringer A, Trappiel M, Berghausen EM, et al. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension. Arch Pharmacol. 2016;389(4):369–379. PMID: 26742933. doi:10.1007/s00210-015-1205-3
   Web of Science ®Google Scholar
• Legchenko E, Chouvarine P, Borchert P, et al. Pparγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med. 2018;10(438):eaao0303. PMID: 29695452. doi:10.1126/scitranslmed.aao0303
   Web of Science ®Google Scholar
• Mannucci E, Monami M, Di Bari M, et al. Cardiac safety profile of rosiglitazone: a comprehensive meta‐analysis of randomized clinical trials. Int J Cardiol. 2010;143:135–140. PMID: 19328563. doi:10.1016/j.ijcard.2009.01.064
   PubMed Web of Science ®Google Scholar
• Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5:6. PMID: 23415113. doi:10.1186/1758-5996-5-6
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu L, Zhang Y, et al. Activation of AMPK inhibits pulmonary arterial smooth muscle cells proliferation. Exp Lung Res. 2014;40:251–258. PMID: 24809794. doi:10.3109/01902148.2014.913092.
   PubMed Web of Science ®Google Scholar
• Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006;55:496–505. PMID: 16443786. doi:10.2337/diabetes.55.02.06.db05-1064
   PubMed Web of Science ®Google Scholar
• Zou MH, Kirkpatrick SS, Davis BJ, et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem. 2004;279:43940–43951. PMID: 15265871. doi:10.1074/jbc.M404421200
   PubMed Web of Science ®Google Scholar
• Dean A, Nilsen M, Loughlin L, et al. Metformin reverses development of pulmonary hypertension via aromatase inhibition. Hypertension. 2016;68(2):446–454. PMID: 27296990. doi:10.1161/HYPERTENSIONAHA.116.07353
   PubMed Web of Science ®Google Scholar
• Agard C, Rolli‐Derkinderen M, Dumas‐de‐La‐Roque E, et al. Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension. Br J Pharmacol. 2009;158:1285–1294. PMID: 19814724. doi:10.1111/j.1476-5381.2009.00445.x
   PubMed Web of Science ®Google Scholar
• Maron BA, Leopold JA. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part II: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension. Circulation. 2015;131:2079–2091. PMID: 26056345. doi:10.1161/CIRCULATIONAHA.114.006980
   Web of Science ®Google Scholar
• Vaillancourt M, Chia P, Sarji S, et al. Autonomic nervous system involvement in pulmonary arterial hypertension. Respir Res. 2017;18(1):201. PMID: 29202826. doi:10.1186/s12931-017-0679-6
   PubMed Web of Science ®Google Scholar
• Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102:865–870. PMID: 10952954. doi:10.1161/01.cir.102.8.865
   PubMed Web of Science ®Google Scholar
• Nootens M, Kaufmann E, Rector T, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol. 1995;26:1581–1585. PMID: 7594089. doi:10.1016/0735-1097(95)00399-1
   PubMed Web of Science ®Google Scholar
• Bristow MR, Minobe W, Rasmussen R, et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Investig. 1992;89:803–815. PMID: 1311717. doi:10.1172/JCI115659
   PubMed Web of Science ®Google Scholar
• Piao L, Fang YH, Parikh KS, et al. GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation. 2012;126:2859–2869. PMID: 23124027. doi:10.1161/CIRCULATIONAHA.112.109868
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Sato N, Asai K, et al. Effects of a pure alpha/beta‐adrenergic receptor blocker on monocrotaline‐induced pulmonary arterial hypertension with right ventricular hypertrophy in rats. Circ J. 2009;73:2337–2341. PMID: 19822980. doi:10.1253/circj.cj-09-0213
   Web of Science ®Google Scholar
• Ghosh S, Gupta M, Xu W, et al. Phosphorylation inactivation of endothelial nitric oxide synthesis in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2016;310:L1199–L1205. PMID: 27130529. doi:10.1152/ajplung.00092.2016
   Web of Science ®Google Scholar
• Perros F, Ranchoux B, Izikki M, et al. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. J Am Coll Cardiol. 2015;65:668–680. PMID: 25677428. doi:10.1016/j.jacc.2014.11.050
   PubMed Web of Science ®Google Scholar
• Perros F, De man FS, Bogaard HJ, et al. Use of β‐blockers in pulmonary hypertension. Circ Heart Fail. 2017;10(4):e003703. PMID: 28364092. doi:10.1161/CIRCHEARTFAILURE.116.003703
   Web of Science ®Google Scholar
• Bogaard HJ, Natarajan R, Mizuno S, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med. 2010;182:652–660. PMID: 20508210. doi:10.1164/rccm.201003-0335OC
   PubMed Web of Science ®Google Scholar
• Drake JI, Gomez-Arroyo J, Dumur CI, et al. Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. Physiol Genom. 2013;45:449–461. PMID: 23632417. doi:10.1152/physiolgenomics.00166.2012
   PubMed Web of Science ®Google Scholar
• de Man FS, Handoko ML, van Ballegoij JJ, et al. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail. 2012;5:97–105. PMID: 22157723. doi:10.1161/CIRCHEARTFAILURE.111.964494
   Web of Science ®Google Scholar
• Grinnan D, Bogaard HJ, Grizzard J, et al. Treatment of group I pulmonary arterial hypertension with carvedilol is safe. Am J Respir Crit Care Med. 2014;189:1562–1564. PMID: 24930531. doi:10.1164/rccm.201311-2025LE
   PubMed Web of Science ®Google Scholar
• Farha S, Saygin D, Park MM, et al. Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial. JCI Insight. 2017;2(16):e95240. PMID: 28814664. doi:10.1172/jci.insight.95240
   Web of Science ®Google Scholar
• van Campen JS, de Boer K, van de Veerdonk MC, et al. Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study. Eur Respir J. 2016;48:787–796. PMID: 27390285. doi:10.1183/13993003.00090-2016
   PubMed Web of Science ®Google Scholar
• de Man FS, Tu L, Handoko ML, et al. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186:780–789. PMID: 22859525. doi:10.1164/rccm.201203-0411OC
   PubMed Web of Science ®Google Scholar
• Morrell NW, Danilov SM, Satyan KB, et al. Right ventricular angiotensin converting enzyme activity and expression is increased during hypoxic pulmonary hypertension. Cardiovasc Res. 1997;34:393–403. PMID: 9205554. doi:10.1016/s0008-6363(97)00049-7
   PubMed Web of Science ®Google Scholar
• Morrell NW, Atochina EN, Morris KG, et al. Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J Clin Invest. 1995;96:1823–1833. PMID: 7560074. doi:10.1172/JCI118228
   PubMed Web of Science ®Google Scholar
• Morrell NW, Morris KG, Stenmark KR. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol. 1995;269:H1186–94. PMID: 7485548. doi:10.1152/ajpheart.1995.269.4.H1186
   PubMed Web of Science ®Google Scholar
• Alpert MA, Pressly TA, Mukerji V, et al. Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest. 1992;102:1407–1412. PMID: 1424860. doi:10.1378/chest.102.5.1407
   PubMed Web of Science ®Google Scholar
• Ikram H, Maslowski AH, Nicholls MG, et al. Haemodynamic and hormonal effects of captopril in primary pulmonary hypertension. Br Heart J. 1982;48:541–545. PMID: 6756445. doi:10.1136/hrt.48.6.541
   PubMedGoogle Scholar
• Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem Pharmacol. 2008;75:781–786. PMID: 17897633. doi:10.1016/j.bcp.2007.08.012
   PubMed Web of Science ®Google Scholar
• Tallant EA, Lu X, Weiss RB, et al. Bovine aortic endothelial cells contain an angiotensin-(1–7) receptor. Hypertension. 1997;29:388–393. PMID: 9039132. doi:10.1161/01.hyp.29.1.388
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Chappell MC, Tallant EA, et al. Counterregulatory actions of angiotensin-(1–7). Hypertension. 1997;30:535–541. PMID: 9322978. doi:10.1161/01.hyp.30.3.535
   PubMed Web of Science ®Google Scholar
• Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1–7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27:523–528. PMID: 8613197. doi:10.1161/01.hyp.27.3.523
   PubMed Web of Science ®Google Scholar
• Nakamoto H, Ferrario CM, Fuller SB, et al. Angiotensin-(1–7) and nitric oxide interaction in renovascular hypertension. Hypertension. 1995;25:796–802. PMID: 7536715. doi:10.1161/01.hyp.25.4.796
   PubMed Web of Science ®Google Scholar
• Tan WSD, Liao W, Zhou S, et al. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. Curr Opin Pharmacol. 2018;40:9–17. PMID: 29288933. doi:10.1016/j.coph.2017.12.002
   PubMed Web of Science ®Google Scholar
• Hemnes AR, Rathinasabapathy A, Austin EA, et al. A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. Eur Respir J. 2018;51(6):pii: 1702638. PMID: 29903860. doi:10.1183/13993003.02638-2017
   Web of Science ®Google Scholar
• Maron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010;121:934–939. PMID: 20177008. doi:10.1161/CIRCULATIONAHA.109.895235
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709–717. PMID: 10471456. doi:10.1056/NEJM199909023411001
   PubMed Web of Science ®Google Scholar
• Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55(suppl6):vi1–vi12. PMID: 16966752. doi:10.1136/gut.2006.099580
   Web of Science ®Google Scholar
• Maron BA, Opotowsky AR, Landzberg MJ, et al. Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. Eur J Heart Fail. 2013;15:277–283. PMID: 23111998. doi:10.1093/eurjhf/hfs173
   Web of Science ®Google Scholar
• Maron BA, Zhang YY, White K, et al. Aldosterone inactivates the endothelin‐B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation. 2012;126:963–974. PMID: 22787113. doi:10.1161/CIRCULATIONAHA.112.094722
   PubMed Web of Science ®Google Scholar
• Maron BA, Oldham WM, Chan SY, et al. Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis. Circulation. 2014;130:168–179. PMID: 25001622. doi:10.1161/CIRCULATIONAHA.113.007690
   Web of Science ®Google Scholar
• Aghamohammadzadeh R, Zhang YY, Stephens TE, et al. Up‐regulation of the mammalian target of rapamycin complex 1 subunit raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension. FASEB J. 2016;30(7):2511–2527. PMID: 27006450. doi:10.1096/fj.201500042
   PubMed Web of Science ®Google Scholar
• Safdar Z, Frost A, Basant A, et al. Spironolactone in pulmonary arterial hypertension: results of a cross-over study. Pulm Circ. 2020;10(2):2045894019898030. PMCID: PMC7219009. PMID: 32426108. doi:10.1177/2045894019898030
   Web of Science ®Google Scholar
• Maron BA, Waxman AB, Opotowsky AR, et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] Study 1 and 2 Trials). Am J Cardiol. 2013;112(5):720–725. PMID: 23751938. doi:10.1016/j.amjcard.2013.04.051
   PubMed Web of Science ®Google Scholar
• Hobbs AJ. Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol Sci. 1997;18(12):484–491. PMID: 9458697. doi:10.1016/s0165-6147(97)01137-1
   PubMed Web of Science ®Google Scholar
• Casserly B, Klinger JR. Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Devel Ther. 2009;3:269–287. PMID: 20054445. doi:10.2147/dddt.s4805
   PubMed Web of Science ®Google Scholar
• Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27(1):47–72. PMID: 16291870. doi:10.1210/er.2005-0014
   PubMed Web of Science ®Google Scholar
• Rosenkranz AC, Woods RL, Dusting GJ, Ritchie RH. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res. 2003;57(2):515–522. PMID: 12566124. doi:10.1016/s0008-6363(02)00667-3
   Web of Science ®Google Scholar
• Klinger JR, Petit RD, Curtin LA, et al. Cardiopulmonary responses to chronic hypoxia in transgenic mice that overexpress ANP. J Appl Physiol. 1993;75(1):198–205. PMID: 7690745. doi:10.1152/jappl.1993.75.1.198.
   Web of Science ®Google Scholar
• Hill NS, Klinger JR, Warburton RR, Pietras L, Wrenn DS. Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension. Am J Physiol. 1994;266(3 Pt 1):L308–15. PMID: 8166300. doi:10.1152/ajplung.1994.266.3.L308
   Web of Science ®Google Scholar
• Angus RM, McCallum MJ, Hulks G, et al. Bronchodilator, cardiovascular, and cyclic guanylyl monophosphate response to high-dose infused atrial natriuretic peptide in asthma. Am Rev Respir Dis. 1993;147(5):1122–1125. PMID: 8387254. doi:10.1164/ajrccm/147.5.1122
   Web of Science ®Google Scholar
• Baliga RS, Zhao L, Madhani M, et al. Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178(8):861–869. PMID: 18689467. doi:10.1164/rccm.200801-121OC
   Web of Science ®Google Scholar
• Klinger JR, Houtchens J, Thaker S, et al. Acute cardiopulmonary hemodynamic effects of brain natriuretic peptide in patients with pulmonary arterial hypertension. Chest. 2005;128(6Suppl):618S–619S. PMID: 16373873. doi:10.1378/chest.128.6_suppl.618S-a
   Web of Science ®Google Scholar
• Klinger JR, Thaker S, Houtchens J, et al. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest. 2006;129(2):417–425. PMID: 16478861. doi:10.1378/chest.129.2.417
   Web of Science ®Google Scholar
• Klinger JR, Warburton RR, Pietras L, Hill NS. Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats. J Appl Physiol. 1998;84(5):1646–1652. PMID: 9572812. doi:10.1152/jappl.1998.84.5.1646
   Web of Science ®Google Scholar
• Jin H, Yang RH, Chen YF, Jackson RM, Oparil S. Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia. J Clin Invest. 1990;85(1):115–120. PMID: 2136863. doi:10.1172/JCI114400.
   Web of Science ®Google Scholar
• Kapoun AM, Liang F, O’Young G, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res. 2004;94(4):453–461. PMID: 14726474. doi:10.1161/01.RES.0000117070.86556.9F
   PubMed Web of Science ®Google Scholar
• VMAC Investigators. (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs. nitroglycerin for treatment of congestive heart failure. A randomized controlled trial. JAMA. 2002;287(12):1531–1540. PMID: 11911755. doi:10.1001/jama.287.12.1531
   Web of Science ®Google Scholar
• Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heartfailure. N Engl J Med. 2000;343(4):246–253. PMID: 10911006. doi:10.1056/NEJM200007273430403
   Web of Science ®Google Scholar
• Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human B-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol. 1999;34:155–162. PMID: 10400005. doi:10.1016/s0735-1097(99)00184-9
   PubMed Web of Science ®Google Scholar
• Michaels AD, Chatterjee K, De Marco T. Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension. J Card Fail. 2005;11(6):425–431. PMID: 16105633. doi:10.1016/j.cardfail.2005.01.009
   Web of Science ®Google Scholar
• Gunaydin S, Imai Y, Takanashi T, et al. The effects of vasoactive intestinal peptide on monocrotaline induced pulmonary hypertensive rabbits following cardiopulmonary bypass: a comparative study with isoproterenol and nitroglycerine. Cardiovasc Surg. 2002;10(2):138–145. PMID: 11888743. doi:10.1016/s0967-2109(01)00126-0
   PubMedGoogle Scholar
• Söderman C, Eriksson LS, Juhlin-Dannfelt A, Lundberg JM, Broman L, Holmgren A. Effect of vasoactive intestinal polypeptide (VIP) on pulmonary ventilation-perfusion relationships and central haemodynamics in healthy subjects. Clin Physiol. 1993;13(6):677–685. PMID: 8119061. doi:10.1111/j.1475-097x.1993.tb00482.x
   Google Scholar
• Maruno K, Absood A, Said SI. VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells. Am J Physiol. 1995;268(6 Pt 1):L1047–51. PMID: 7541947. doi:10.1152/ajplung.1995.268.6.L1047
   PubMed Web of Science ®Google Scholar
• Cox CP, Linden J, Said SI. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). Peptides. 1984;5(2):325–328. PMID: 6206481. doi:10.1016/0196-9781(84)90228-6
   PubMed Web of Science ®Google Scholar
• Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest. 2003;111(9):1339–1346. PMID: 12727925 PMID: 12727925. doi:10.1172/JCI17500
   PubMed Web of Science ®Google Scholar
• Galie N, Boonstra A, Ewert R. Effects of inhaled aviptadil (Vasoactive Intestinal Peptide) in patients with pulmonary arterial hypertension (PAH). Am J Resp Crit Care Med. 2010;181:A2516.
   Web of Science ®Google Scholar
• Nicholls MG, Lainchbury JG, Lewis LK, et al. Bioactivity of adrenomedullin and proadrenomedullin N-terminal 20 peptide in man. Peptides. 2001;22(11):1745–1752. PMID: 11754960. doi:10.1016/s0196-9781(01)00508-3
   Web of Science ®Google Scholar
• Kakishita M, Nishikimi T, Okano Y, et al. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin Sci (Lond). 1999;96(1):33–39. PMID: 9857104. doi:10.1042/CS19980070
   PubMed Web of Science ®Google Scholar
• Shimukubo T, Sakata J, Kitamura K, Kangawa K, Matsuo H, Eto T. Augmented adrenomedullin concentrations in right ventricle and plasma of experimental pulmonary hypertension. Life Sci. 1995;57(19):1771–1779. PMID: 7475919. doi:10.1016/0024-3205(95)02155-c
   Web of Science ®Google Scholar
• Yoshibayashi M, Kamiya T, Kitamura K, et al. Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients <20 years of age. Am J Cardiol. 1997;79(11):1556–1558. PMID: 9185657. doi:10.1016/s0002-9149(97)00195-1
   PubMed Web of Science ®Google Scholar
• Nishikimi T, Nagata S, Sasaki T, et al. Plasma concentrations of adrenomedullin correlate with the extent of pulmonary hypertension in patients with mitral stenosis. Heart. 1997;78(4):390–395. PMID: 9404257. doi:10.1136/hrt.78.4.390
   Web of Science ®Google Scholar
• Yoshihara F, Nishikimi T, Horio T, et al. Eur Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline. J Pharmacol. 1998;355(1):33–39. PMID: 9754936. doi:10.1016/s0014-2999(98)00475-0
   Google Scholar
• Nagaya N, Nishikimi T, Uematsu M, et al. Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension. Heart. 2000;84(6):653–658. PMID: 11083748. doi:10.1136/heart.84.6.653
   Web of Science ®Google Scholar
• Nagaya N, Miyatake K, Kyotani S, et al. Pulmonary vasodilator response to adrenomedullin in patients with pulmonary hypertension. Hypertens Res. 2003;26(Suppl):S141–6. PMID: 12630825. doi:10.1291/hypres.26.s141
   PubMed Web of Science ®Google Scholar
• Nagaya N, Kyotani S, Uematsu M, et al. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation. 2004;109(3):351–356. PMID: 14718403. doi:10.1161/01.CIR.0000109493.05849.14
   PubMed Web of Science ®Google Scholar
• Giordano N, Papakostas P, Lucani B, et al. Serum relaxin in systemic sclerosis. J Rheumatol. 2005;32:2164–2166. PMID: 16265695.
   PubMed Web of Science ®Google Scholar
• Tozzi CA, Poiani GJ, McHugh NA, et al. Recombinant human relaxin reduces hypoxic pulmonary hypertension in the rat. Pulm Pharmacol Ther. 2005;18:346–353. PMID: 15939313. doi:10.1016/j.pupt.2005.01.003
   Web of Science ®Google Scholar
• Mazurek JA, Horne BD, Kelesidis I, et al. Relaxin levels in pulmonary hypertension: a comparison between pulmonary arterial hypertension and diastolic heart failure-induced pulmonary hypertension. J Heart Lung Transplant. 2013;32(3):371–374. PMID: 23273743. doi:10.1016/j.healun.2012.11.030
   Web of Science ®Google Scholar
• Lee SL, Simon AR, Wang WW, Fanburg BL. H(2)O(2) signals 5-HT-induced ERK MAP kinase activation and mitogenesis of smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2001;281(3):L646–52. doi:10.1152/ajplung.2001.281.3.L646
   Web of Science ®Google Scholar
• Eddahibi S, Guignabert C, Barlier-Mur AM, et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation. 2006;113(15):1857–1864. PMID: 16606791. doi:10.1161/CIRCULATIONAHA.105.591321
   Web of Science ®Google Scholar
• Morrell NW, Archer SL, Stenmark KR, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43(12Suppl S):13S–24S. PMID: 15194174. doi:10.1016/j.jacc.2004.02.029
   Web of Science ®Google Scholar
• MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol. 2000;131(2):161–168. doi:10.1038/sj.bjp.0703570
   PubMed Web of Science ®Google Scholar
• Morecroft I, Heeley RP, Prentice HM, Kirk A, MacLean MR. 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol. 1999;128(3):730–734. PMID: 10516655. doi:10.1038/sj.bjp.0702841
   Web of Science ®Google Scholar
• Wilson SM, Mason HS, Ng LC, et al. Role of basal extracellular Ca2+ entry during 5-HT-induced vasoconstriction of canine pulmonary arteries. Br J Pharmacol. 2005;144(2):252–264. PMID: 15655514. doi:10.1038/sj.bjp.0706077
   Web of Science ®Google Scholar
• Liu Y, Fanburg BL. Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1. Am J Respir Cell Mol Biol. 2006;34(2):182–191. PMID: 16195541. doi:10.1165/rcmb.2005-0163OC
   Web of Science ®Google Scholar
• Mair KM, MacLean MR, Morecroft I, Dempsie Y, Palmer TM. Novel interactions between the 5-HT transporter, 5-HT1B receptors and Rho kinase in vivo and in pulmonary fibroblasts. Br J Pharmacol. 2008;155(4):606–616. PMID: 18695640. doi:10.1038/bjp.2008.310
   Web of Science ®Google Scholar
• Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995;99(3):249–254. PMID: 7653484. doi:10.1016/s0002-9343(99)80156-9
   PubMed Web of Science ®Google Scholar
• Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335(9):609–616. PMID: 8692238. doi:10.1056/NEJM199608293350901
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001;108(8):1141–1150. PMID: 11602621. doi:10.1172/JCI12805
   PubMed Web of Science ®Google Scholar
• Fanburg BL, Lee SL. A new role for an old molecule: serotonin as a mitogen. Am J Physiol. 1997;272(5 Pt 1):L795–806. PMID: 9176241. doi:10.1152/ajplung.1997.272.5.L795
   PubMed Web of Science ®Google Scholar
• Kren V, Eich E, Pertz HH. Pergolide, terguride and N,N’-spacer-linked oligomers of both interact with 5-HT2A receptors of rat tail artery. Physiol Res. 2004;53(1):35–43. PMID: 14984312.
   Web of Science ®Google Scholar
• Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;303(2):791–804. PMID: 12388666. doi:10.1124/jpet.102.039867
   PubMed Web of Science ®Google Scholar
• Jähnichen S, Horowski R, Pertz HH. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol. 2005;513(3):225–228. PMID: 15862804. doi:10.1016/j.ejphar.2005.03.010
   PubMed Web of Science ®Google Scholar
• Dumitrascu R, Kulcke C, Königshoff M, et al. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J. 2011;37(5):1104–1118. PMID: 20947677. doi:10.1183/09031936.00126010
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Al-Hiti H, Vonk-Noordegraaf A, et al. Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs. placebo in subjects with pulmonary arterial hypertension: results of A Double Blind, Randomised, Prospective Phase IIa Study. Am J Resp Crit Care Med. 2012;185:A2496.
   Google Scholar
• Lahm T, Tuder RM, Petrache I. Progress in solving the sex hormone paradox in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2014;307(1):L7–26. PMID: 24816487. doi:10.1152/ajplung.00337.2013
   PubMed Web of Science ®Google Scholar
• Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216–223. PMID: 3605900. doi:10.7326/0003-4819-107-2-216
   PubMed Web of Science ®Google Scholar
• Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how reveal differs from historic and non‐us contemporary registries. Chest. 2011;139:128–137. PMID: 20558556. doi:10.1378/chest.10-0075
   PubMed Web of Science ®Google Scholar
• McGoon MD, Benza RL, Escribano‐Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62:D51–D59. PMID: 24355642. doi:10.1016/j.jacc.2013.10.023
   PubMed Web of Science ®Google Scholar
• Prins KW, Thenappan T. World health organization group i pulmonary hypertension: epidemiology and pathophysiology. Cardiol Clin. 2016;34:363–374. PMID: 27443134. doi:10.1016/j.ccl.2016.04.001
   PubMed Web of Science ®Google Scholar
• Chen X, Austin ED, Talati M, et al. Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects. Eur Respir J. 2017;50:1602337. PMID: 28775043. doi:10.1183/13993003.02337-2016
   Web of Science ®Google Scholar
• Foderaro A, Ventetuolo CE. Pulmonary arterial hypertension and the sex hormone paradox. Curr Hypertens Rep. 2016;18(11):84. PMID: 27832457. doi:10.1007/s11906-016-0689-7
   Web of Science ®Google Scholar
• Ventetuolo CE, Baird GL, Barr RG, et al. Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men. Am J Respir Crit Care Med. 2016;193:1168–1175. PMID: 26651504. doi:10.1164/rccm.201509-1785OC
   Web of Science ®Google Scholar
• Frump AL, Goss KN, Vayl A, et al. Estradiol improves right ventricular function in rats with severe angioproliferative pulmonary hypertension: effects of endogenous and exogenous sex hormones. Am J Physiol Lung Cell Mol Physiol. 2015;308:L873–L890. PMID: 25713318. doi:10.1152/ajplung.00006.2015
   Web of Science ®Google Scholar
• Liu A, Philip J, Vinnakota KC, et al. Estrogen maintains mitochondrial content and function in the right ventricle of rats with pulmonary hypertension. Physiol Rep. 2017;5(6):e13157. PMID: 28320896. doi:10.14814/phy2.13157
   Web of Science ®Google Scholar
• Jacobs W, van de Veerdonk MC, Trip P, et al. The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. Chest. 2014;145(6):1230–1236. PMID: 24306900. doi:10.1378/chest.13-1291
   PubMed Web of Science ®Google Scholar
• Kawut SM, Al-Naamani N, Agerstrand C, et al. Determinants of right ventricular ejection fraction in pulmonary arterial hypertension. Chest. 2009;135(3):752–759. PMID: 18849396. doi:10.1378/chest.08-1758
   Web of Science ®Google Scholar
• Baird GL, Archer-Chicko C, Barr RG, et al. Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension. Eur Respir J. 2018;51:1800467. PMID: 29954925. doi:10.1183/13993003.00467-2018
   PubMed Web of Science ®Google Scholar
• Simpson ER, Clyne C, Rubin G, et al. Aromatase—a brief overview. Annu Rev Physiol. 2002;64:93–127. PMID: 11826265. doi:10.1146/annurev.physiol.64.081601.142703
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor‐positive breast cancer. J Oncol Pract. 2010;6:243–246. PMID: 21197188. doi:10.1200/JOP.000082
   PubMedGoogle Scholar
• Mair KM, Wright AF, Duggan N, et al. Sex‐dependent influence of endogenous estrogen in pulmonary hypertension. Am J Respir Crit Care Med. 2014;190:456–467. PMID: 24956156. doi:10.1164/rccm.201403-0483OC
   PubMed Web of Science ®Google Scholar
• Kawut SM, Archer‐Chicko CL, DeMichele A, et al. Anastrozole in pulmonary arterial hypertension. A randomized, double‐blind, placebo‐controlled trial. Am J Respir Crit Care Med. 2017;195:360–368. PMID: 27602993. doi:10.1164/rccm.201605-1024OC
   Web of Science ®Google Scholar
• Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2:205–213. PMID: 12612646. doi:10.1038/nrd1031
   PubMed Web of Science ®Google Scholar
• van Empel VP, Lee J, Williams TJ, et al. Iron deficiency in patients with idiopathic pulmonary arterial hypertension. Heart Lung Circ. 2014;23:287–292. PMID: 24094431. doi:10.1016/j.hlc.2013.08.007
   PubMed Web of Science ®Google Scholar
• Rhodes CJ, Wharton J, Howard L, et al. Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J. 2011;38:1453–1460. PMID: 21478213. doi:10.1183/09031936.00037711
   PubMed Web of Science ®Google Scholar
• Ruiter G, Lankhorst S, Boonstra A, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J. 2011;37:1386–1391. PMID: 20884742. doi:10.1183/09031936.00100510
   PubMed Web of Science ®Google Scholar
• Soon E, Treacy CM, Toshner MR, et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax. 2011;66(4):326–332. PMID: 21297151. doi:10.1136/thx.2010.147272
   PubMed Web of Science ®Google Scholar
• Krasuski RA, Hart SA, Smith B, et al. Association of anemia and long-term survival in patients with pulmonary hypertension. Int J Cardiol. 2011;150(3):291–295. PMID: 20472313. doi:10.1016/j.ijcard.2010.04.038
   Web of Science ®Google Scholar
• Ruiter G, Manders E, Happe CM, et al. Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency. Pulm Circ. 2015;5(3):466–472. PMID: 26401247. doi:10.1086/682217
   Web of Science ®Google Scholar
• Viethen T, Gerhardt F, Dumitrescu D, et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol. 2014;175:233–239. PMID: 24880481. doi:10.1016/j.ijcard.2014.04.233
   PubMed Web of Science ®Google Scholar
• Robinson JC, Graham BB, Rouault TC, et al. The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension. Am J Respir Cell Mol Biol. 2014;51(6):721–729. PMID: 24988529. doi:10.1165/rcmb.2014-0021TR
   PubMed Web of Science ®Google Scholar
• Callejo M, Mondejar-Parreño G, Esquivel-Ruiz S, et al. Total, bioavailable, and free vitamin D levels and their prognostic value in pulmonary arterial hypertension. J Clin Med. 2020;9(2):448. PMID: 32041235. doi:10.3390/jcm9020448
   Web of Science ®Google Scholar
• Yu H, Xu M, Dong Y, Liu J. (OH)2D3 attenuates pulmonary arterial hypertension via microRNA-204 mediated Tgfbr2/Smad signaling. Exp Cell Res. 2018;362(2):311–323. PMID: 29196166. doi:10.1016/j.yexcr.2017.11.032.
   Web of Science ®Google Scholar
• Mirdamadi A, Moshkdar P. Benefits from the correction of vitamin D deficiency in patients with pulmonary hypertension. Caspian J Intern Med. 2016;7(4):253–259. PMID: 27999642.
   Google Scholar
• Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109:3122–3131. PMID: 15226229. doi:10.1161/01.CIR.0000133187.74800.B9
   PubMed Web of Science ®Google Scholar
• Pascal JM. The comings and goings of PARP-1 in response to DNA damage. DNA Repair (Amst). 2018;71:177–182. PMID: 30177435. doi:10.1016/j.dnarep.2018.08.022
   PubMed Web of Science ®Google Scholar
• Wheelhouse NM, Chan YS, Gillies SE, et al. TNF-alpha induced DNA damage in primary murine hepatocytes. Int J Mol Med. 2003;12:889–894. PMID: 14612962.
   PubMed Web of Science ®Google Scholar
• Fehsel K, Kolb-Bachofen V, Kolb H. Analysis of TNF alpha-induced DNA strand breaks at the single cell level. Am J Pathol. 1991;139:251–254. PMID: 1867316.
   PubMed Web of Science ®Google Scholar
• Gorenne I, Kumar S, Gray K, et al. Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis. Circulation. 2013;127:386–396. PMID: 23224247. doi:10.1161/CIRCULATIONAHA.112.124404
   PubMed Web of Science ®Google Scholar
• Meloche J, Pflieger A, Vaillancourt M, et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation. 2014;129:786–797. PMID: 24270264. doi:10.1161/CIRCULATIONAHA.113.006167
   PubMed Web of Science ®Google Scholar
• Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2014;117:421–426. PMID: 15137936. doi:10.1016/s0092-8674(04)00452-0
   Web of Science ®Google Scholar
• Sengupta A, Molkentin JD, Paik JH, et al. FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. J Biol Chem. 2011;286(9):7468–7478. doi:10.1074/jbc.M110.179242
   Web of Science ®Google Scholar
• Savai R, Al‐Tamari HM, Sedding D, et al. Pro‐proliferative and inflammatory signaling converge on FoXO1 transcription factor in pulmonary hypertension. Nat Med. 2014;20:1289–1300. PMID: 25344740. doi:10.1038/nm.3695
   Web of Science ®Google Scholar
• Deng C, Zhong Z, Wu D, et al. Role of FoxO1 and apoptosis in pulmonary vascular remolding in a rat model of chronic thromboembolic pulmonary hypertension. Sci Rep. 2017;7(1):2270. PMID: 28536427. doi:10.1038/s41598-017-02007-5
   Web of Science ®Google Scholar
• Nehate C, Jain S, Saneja A, et al. Paclitaxel formulations: challenges and novel delivery options. Curr Drug Deliv. 2014;11(6):666–686. PMID: 24909147. doi:10.2174/1567201811666140609154949
   PubMed Web of Science ®Google Scholar
• Veldhoen RA, Banman SL, Hemmerling DR, et al. The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis. Oncogene. 2013;32(6):736–746. PMID: 22430212. doi:10.1038/onc.2012.92
   PubMed Web of Science ®Google Scholar
• Goto T, Takano M, Hirata J, Tsuda H. The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers. Br J Cancer. 2008;98(6):1068–1075. PMID: 18319717. doi:10.1038/sj.bjc.6604279
   Web of Science ®Google Scholar
• Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell. 2013;152(6):1237–1251. PMID: 23498934. doi:10.1016/j.cell.2013.02.014
   PubMed Web of Science ®Google Scholar
• Yin Y, Wu X, Yang Z, et al. The potential efficacy of R8-modified paclitaxel loaded liposomes on pulmonary arterial hypertension. Pharm Res. 2013;30:2050–2062. PMID: 23756757. doi:10.1007/s11095-013-1058-8
   PubMed Web of Science ®Google Scholar
• Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61(2):227–237. PMID: 14736539. doi:10.1016/j.cardiores.2003.11.026
   PubMed Web of Science ®Google Scholar
• Dai Y, Chen X, Song X, et al. Immunotherapy of endothelin-1 receptor Type A for pulmonary arterial hypertension. J Am Coll Cardiol. 2019;73(20):2567–2580. PMID: 31118151. doi:10.1016/j.jacc.2019.02.067
   PubMed Web of Science ®Google Scholar
• Fessel JP, Loyd JE, Austin ED. The genetics of pulmonary arterial hypertension in the postBMPR2 era. Pulm Circ. 2011;1(3):305–319. doi:10.4103/2045-8932.87293
   Google Scholar
• Kaji EH, Leiden JM. Gene and stem cell therapies. JAMA. 2001;285(5):545–550. doi:10.1001/jama.285.5.545
   PubMed Web of Science ®Google Scholar
• Reynolds AM, Xia W, Holmes MD, et al. Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonaryhypertension. Am J Physiol Lung Cell Mol Physiol. 2007;292(5):L1182–92. doi:10.1152/ajplung.00020.2006
   PubMed Web of Science ®Google Scholar
• Lee CS, Bishop ES, Zhang R, et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 2017;4(2):43–63. doi:10.1016/j.gendis.2017.04.001
   PubMed Web of Science ®Google Scholar
• Bisserier M, Pradhan N, Lahouaria H. Current and emerging therapeutic approaches to pulmonary hypertension. Rev Cardiovasc Med. 2020;21(2):163–179. doi:10.31083/j.rcm.2020.02.597
   Web of Science ®Google Scholar
• Lee R, Feinbaum R, Ambros V. A short history of a short RNA. Cell. 2004;116(Suppl):S89–S92,1 p. following S96. doi:10.1016/s0092-8674(04)00035-2
   Google Scholar
• Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102–114. doi:10.1038/nrg2290
   PubMed Web of Science ®Google Scholar
• Giannakakis A, Sandaltzopoulos R, Greshock J, et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther. 2008;7(2):255–264. PMID: 18059191. doi:10.4161/cbt.7.2.5297
   PubMed Web of Science ®Google Scholar
• Fasanaro P, Greco S, Lorenzi M, et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem. 2009;284(50):35134–35143. PMID: 19826008. doi:10.1074/jbc.M109.052779
   PubMed Web of Science ®Google Scholar
• Li S, Ran Y, Zhang D, et al. MicroRNA-138 plays a role in hypoxic pulmonary vascular remodelling by targeting Mst1. Biochem J. 2013;452(2):281–291. PMID: 23485012. doi:10.1042/BJ20120680
   Web of Science ®Google Scholar
• Caruso P, Dempsie Y, Stevens HC, et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res. 2012;111(3):290–300. PMID: 22715469. doi:10.1161/CIRCRESAHA.112.267591
   PubMed Web of Science ®Google Scholar
• Gou D, Ramchandran R, Peng X, et al. miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol. 2012;303(8):L682–91. PMID: 22886504. doi:10.1152/ajplung.00344.2011
   PubMed Web of Science ®Google Scholar
• Kang K, Peng X, Zhang X, et al. MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells. J Biol Chem. 2013;288(35):25414–25427. PMID: 23853098. doi:10.1074/jbc.M113.460287
   PubMed Web of Science ®Google Scholar
• Courboulin A, Paulin R, Giguère NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208(3):535–548. PMID: 21321078. doi:10.1084/jem.20101812
   PubMed Web of Science ®Google Scholar
• Jalali S, Ramanathan GK, Parthasarathy PT, et al. Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. PLoS One. 2012;7(10):e46808. doi:10.1371/journal.pone.0046808
   PubMed Web of Science ®Google Scholar
• Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med. 2009;27(5):351–357. PMID: 19711245. doi:10.1055/s-0029-1237423
   PubMed Web of Science ®Google Scholar
• Hambach L, Ling KW, Pool J, et al. Hypomethylating drugs convert HA-1 negative solid tumors into targets for stem cell based immunotherapy. Blood. 2009;113(12):2715–2722. PMID: 19096014. doi:10.1182/blood-2008-05-158956
   PubMed Web of Science ®Google Scholar
• Chueh AC, Tse JW, Tögel L, Mariadason JM. Mechanisms of histone deacetylase inhibitor-regulated gene expression in cancer cells. Antioxid Redox Signal. 2015;23(1):66–84. PMC 4492771. PMID 24512308. doi:10.1089/ars.2014.5863
   Web of Science ®Google Scholar
• Zhao L, Chen CN, Hajji N, et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation. 2012;126(4):455–467. PMID: 22711276. doi:10.1161/CIRCULATIONAHA.112.103176
   PubMed Web of Science ®Google Scholar
• Kim J, Kang Y, Kojima Y, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med. 2013;19(1):74–82. PMID: 23263626. doi:10.1038/nm.3040
   PubMed Web of Science ®Google Scholar
• Kim J, Hwangbo C, Hu X, et al. Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension. Circulation. 2015;131(2):190–199. PMID: 25336633. doi:10.1161/CIRCULATIONAHA.114.013339
   Web of Science ®Google Scholar
• Borck PC, Guo LW, Plutzky J. BET epigenetic reader proteins in cardiovascular transcriptional programs. Circ Res. 2020;126(9):1190–1208. PMID: 32324495. doi:10.1161/CIRCRESAHA.120.315929
   PubMed Web of Science ®Google Scholar
• Meloche J, Potus F, Vaillancourt M, et al. Bromodomain-containing protein 4: the epigenetic origin of pulmonary arterial hypertension. Circ Res. 2015;117(6):525–535. PMID: 26224795. doi:10.1161/CIRCRESAHA.115.307004
   Web of Science ®Google Scholar